Literature DB >> 22345652

Production of autoantibodies against citrullinated antigens/peptides by human B cells.

Maria F Bellatin1, Mei Han, Margarita Fallena, Lin Fan, Donglan Xia, Nancy Olsen, Valerie Branch, David Karp, Peter Stastny.   

Abstract

Autoantibodies against citrullinated protein Ags (ACPA) are associated with the development of rheumatoid arthritis (RA). This immune response against citrullinated protein Ags, which is thought to be facilitated by certain MHC HLA-DR alleles, is highly specific for this disease and has been speculated to be involved in the pathogenesis. We have previously studied cultures of B cells for the production of Abs against HLA Ags. The aim of the current study was to examine the role of B cells in the production of ACPA in patients with RA. Peripheral blood B cells from RA patients and healthy people were cultured with EL4-B5, a murine cell line expressing human CD40L, and with T cell factors to stimulate the in vitro production of Abs by B cells isolated from peripheral blood. ACPA were produced by cultured B cells from RA patients, as determined by reactivity to cyclic citrullinated peptide (CCP). The results showed that 22% of the healthy persons tested also had B cells that could produce ACPA. Patients with HLA-DR alleles carrying the RA-associated shared epitope appeared to have more B cells with autoimmune potential for CCP than those without such HLA alleles (odds ratio 8.1, p = 0.001). In healthy individuals, anti-CCP-producing B cells were also observed more frequently if the RA-associated MHC genes were present (odds ratio 8.0, p = 0.01). Analysis of B cells in cultures may shed light on the interaction of genetic and environmental factors in the development of RA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345652     DOI: 10.4049/jimmunol.1100577

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.

Authors:  Anca I Catrina; Kevin D Deane; Jose U Scher
Journal:  Rheumatology (Oxford)       Date:  2014-12-23       Impact factor: 7.580

2.  Autoantibodies From Single Circulating Plasmablasts React With Citrullinated Antigens and Porphyromonas gingivalis in Rheumatoid Arthritis.

Authors:  Song Li; Yangsheng Yu; Yinshi Yue; Hongyan Liao; Wanqin Xie; Jessica Thai; Ted R Mikuls; Geoffrey M Thiele; Michael J Duryee; Harlan Sayles; Jeffrey B Payne; Lynell W Klassen; James R O'Dell; Zhixin Zhang; Kaihong Su
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

3.  Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients.

Authors:  Eszter Szarka; Fruzsina Babos; Anna Magyar; Krisztina Huber; Zoltán Szittner; Krisztián Papp; József Prechl; Judit Pozsgay; Zsuzsa Neer; Monika Ádori; György Nagy; Bernadette Rojkovich; Tamás Gáti; Judit Kelemen; Zsuzsanna Baka; Márta Brózik; Borbála Pazár; Gyula Poór; Ferenc Hudecz; Gabriella Sármay
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

Review 4.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

5.  Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.

Authors:  Adam J Pelzek; Caroline Grönwall; Pamela Rosenthal; Jeffrey D Greenberg; Mandy McGeachy; Larry Moreland; William F C Rigby; Gregg J Silverman
Journal:  Arthritis Rheumatol       Date:  2017-05-03       Impact factor: 10.995

Review 6.  The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses.

Authors:  S Modi; M Soejima; M C Levesque
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

7.  Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

Authors:  Dániel Szili; Marcell Cserhalmi; Zsuzsanna Bankó; György Nagy; David E Szymkowski; Gabriella Sármay
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

Review 8.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

Review 9.  Preclinical rheumatoid arthritis (autoantibodies): an updated review.

Authors:  Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

10.  In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles.

Authors:  Judit Pozsgay; Fruzsina Babos; Katalin Uray; Anna Magyar; Gergő Gyulai; Éva Kiss; György Nagy; Bernadette Rojkovich; Ferenc Hudecz; Gabriella Sármay
Journal:  Arthritis Res Ther       Date:  2016-01-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.